Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04062981 · ClinicalTrials.gov registry record · Phase 1
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
A Phase 1 study of Lennox Gastaut Syndrome, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT04062981 is a Phase 1 study of Lennox Gastaut Syndrome that has completed, run by SK Life Science. The registered enrollment target is 15 participants, below the 606-participant average among 10 other Lennox Gastaut Syndrome trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04062981, a Phase 1 study of Lennox Gastaut Syndrome, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).
Conditions Studied
Interventions
- DRUG Carisbamate
Study Locations (5)
Maryland
- Johns Hopkins Hospital - Baltimore
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Oregon
- Oregon Health and Science University - Portland
Utah
- The University of Utah School of Medicine - Primary Children's Hospital (Primary Children's Medical Center) - Salt Lake City
Washington
- UW Valley Medical Center - Renton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04062981
The ClinicalTrials.gov registry entry for NCT04062981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 606-participant average among 10 other Lennox Gastaut Syndrome trials with a reported enrollment target (98% lower). The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lennox Gastaut Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Carisbamate is the first listed.
NCT04062981 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Maryland, New Hampshire, Oregon.
Frequently Asked Questions
What is clinical trial NCT04062981 about?
NCT04062981 is a clinical study titled "Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome". Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).
What is the current status of trial NCT04062981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-05-03. Estimated completion is 2022-12-14.
What conditions does trial NCT04062981 study?
This clinical trial studies the following conditions: Lennox Gastaut Syndrome.
What interventions are being tested in trial NCT04062981?
The interventions under investigation include: Carisbamate (DRUG).
Who is sponsoring clinical trial NCT04062981?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04062981 being conducted?
This trial has 5 study locations across Maryland, New Hampshire, Oregon, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lennox Gastaut Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
COMPLETED · Phase 1
-
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
COMPLETED · Phase 1
-
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
RECRUITING · Phase 3
-
Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
RECRUITING
-
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
RECRUITING · Phase 3
-
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.